Annamaria Biczok1,2, Theo Kraus3,4, Bogdana Suchorska5,6, Nicole A Terpolilli5,6, Jun Thorsteinsdottir5,6, Armin Giese3,6, Joerg C Tonn5,6, Christian Schichor5,6. 1. Department of Neurosurgery, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. annamaria.biczok@med.uni-muenchen.de. 2. German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. annamaria.biczok@med.uni-muenchen.de. 3. Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany. 4. University Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. 5. Department of Neurosurgery, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. 6. German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
INTRODUCTION: Transcriptional activating mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene occur at high frequency in various types of solid tumors and have also been reported for meningiomas. Especially for atypical and anaplastic meningiomas, the prognostic relevance of TERT promoter mutation is yet unclear. The present study aimed to analyze the frequency of TERT promoter mutation and define its long-term prognostic significance beyond clinical and histological factors in a cohort of meningiomas WHO grade II and III. METHODS: Patients undergoing surgical resection of aggressive meningiomas were included. Analysis for C228T and C250T mutation in the TERT promoter region was performed using PCR method. Patients were stratified into two groups (TERT mutated vs. TERT wild type). Univariate analysis was conducted using molecular and histological factors. RESULTS: 87 patients with atypical (N = 72) and anaplastic meningiomas (N = 15) were included in the study. TERT promoter region was found to be mutated in 4 WHO grade II and 2 WHO grade III meningiomas. TERT promoter mutation was associated with shorter progression free survival than TERT wild type meningiomas (median PFS 12.5 vs. 26 months, p = .004). In the univariate analysis, TERT promoter mutation had a strong prognostic value on overall survival (p = .009) and progression free survival. CONCLUSIONS: Presence of TERT promoter mutation is associated with shorter progression free survival and overall survival in meningiomas WHO grade II and III. In these tumors, TERT promoter mutation should be considered as a clinically relevant prognostic factor to identify high risk patients.
INTRODUCTION: Transcriptional activating mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene occur at high frequency in various types of solid tumors and have also been reported for meningiomas. Especially for atypical and anaplastic meningiomas, the prognostic relevance of TERT promoter mutation is yet unclear. The present study aimed to analyze the frequency of TERT promoter mutation and define its long-term prognostic significance beyond clinical and histological factors in a cohort of meningiomas WHO grade II and III. METHODS:Patients undergoing surgical resection of aggressive meningiomas were included. Analysis for C228T and C250T mutation in the TERT promoter region was performed using PCR method. Patients were stratified into two groups (TERT mutated vs. TERT wild type). Univariate analysis was conducted using molecular and histological factors. RESULTS: 87 patients with atypical (N = 72) and anaplastic meningiomas (N = 15) were included in the study. TERT promoter region was found to be mutated in 4 WHO grade II and 2 WHO grade III meningiomas. TERT promoter mutation was associated with shorter progression free survival than TERT wild type meningiomas (median PFS 12.5 vs. 26 months, p = .004). In the univariate analysis, TERT promoter mutation had a strong prognostic value on overall survival (p = .009) and progression free survival. CONCLUSIONS: Presence of TERT promoter mutation is associated with shorter progression free survival and overall survival in meningiomas WHO grade II and III. In these tumors, TERT promoter mutation should be considered as a clinically relevant prognostic factor to identify high risk patients.
Authors: Felix Sahm; Daniel Schrimpf; Damian Stichel; David T W Jones; Thomas Hielscher; Sebastian Schefzyk; Konstantin Okonechnikov; Christian Koelsche; David E Reuss; David Capper; Dominik Sturm; Hans-Georg Wirsching; Anna Sophie Berghoff; Peter Baumgarten; Annekathrin Kratz; Kristin Huang; Annika K Wefers; Volker Hovestadt; Martin Sill; Hayley P Ellis; Kathreena M Kurian; Ali Fuat Okuducu; Christine Jungk; Katharina Drueschler; Matthias Schick; Melanie Bewerunge-Hudler; Christian Mawrin; Marcel Seiz-Rosenhagen; Ralf Ketter; Matthias Simon; Manfred Westphal; Katrin Lamszus; Albert Becker; Arend Koch; Jens Schittenhelm; Elisabeth J Rushing; V Peter Collins; Stefanie Brehmer; Lukas Chavez; Michael Platten; Daniel Hänggi; Andreas Unterberg; Werner Paulus; Wolfgang Wick; Stefan M Pfister; Michel Mittelbronn; Matthias Preusser; Christel Herold-Mende; Michael Weller; Andreas von Deimling Journal: Lancet Oncol Date: 2017-03-15 Impact factor: 41.316
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling Journal: Acta Neuropathol Date: 2013-10-24 Impact factor: 17.088
Authors: Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling Journal: J Natl Cancer Inst Date: 2015-12-13 Impact factor: 13.506
Authors: Tareq A Juratli; Christian Thiede; Mara V A Koerner; Shilpa S Tummala; Dirk Daubner; Ganesh M Shankar; Erik A Williams; Maria Martinez-Lage; Silke Soucek; Katja Robel; Tristan Penson; Mechthild Krause; Steffen Appold; Matthias Meinhardt; Thomas Pinzer; Julie J Miller; Dietmar Krex; Heather A Ely; Ian M Silverman; Jason Christiansen; Gabriele Schackert; Hiroaki Wakimoto; Matthias Kirsch; Priscilla K Brastianos; Daniel P Cahill Journal: Oncotarget Date: 2017-11-24
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Victor M Lu; Anshit Goyal; Adrian Lee; Mark Jentoft; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2018-12-01 Impact factor: 4.130
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2021-03-14 Impact factor: 4.553
Authors: Matthias Preusser; Antonio Silvani; Emilie Le Rhun; Riccardo Soffietti; Giuseppe Lombardi; Juan Manuel Sepulveda; Petter Brandal; Lucy Brazil; Alice Bonneville-Levard; Veronique Lorgis; Elodie Vauleon; Jacoline Bromberg; Sara Erridge; Alison Cameron; Florence Lefranc; Paul M Clement; Sarah Dumont; Marc Sanson; Charlotte Bronnimann; Carmen Balaná; Niklas Thon; Joanne Lewis; Maximilian J Mair; Philipp Sievers; Julia Furtner; Josef Pichler; Jordi Bruna; Francois Ducray; Jaap C Reijneveld; Christian Mawrin; Martin Bendszus; Christine Marosi; Vassilis Golfinopoulos; Corneel Coens; Thierry Gorlia; Michael Weller; Felix Sahm; Wolfgang Wick Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: So Yeon Won; Jun Ho Lee; Narae Lee; Yae Won Park; Sung Soo Ahn; Jinna Kim; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Marcus Unterrainer; Viktoria Ruf; Katharina von Rohr; Bogdana Suchorska; Lena Maria Mittlmeier; Leonie Beyer; Matthias Brendel; Vera Wenter; Wolfgang G Kunz; Peter Bartenstein; Jochen Herms; Maximilian Niyazi; Jörg C Tonn; Nathalie Lisa Albert Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244